Echinacoside (Synonyms: Kusaginin, NSC 603831, trans-Acteoside, trans-Verbascoside) |
Catalog No.GN10422
One-Click Copy Product Info
|
Echinacoside is a phenylethanoid glycoside isolated from Cistanche tubulosa with potent antioxidant and anti-inflammatory effects.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 82854-37-3
Sample solution is provided at 25 µL, 10mM.
Echinacoside is a phenylethanoid glycoside isolated from Cistanche tubulosa with potent antioxidant and anti-inflammatory effects[1]. Echinacoside is commonly used in research on neurodegenerative diseases (Parkinson's disease, Alzheimer's disease), cardiovascular health, and skin protective agents[2,3,4].
In vitro, Echinacoside (20, 50, 100μg/mL) treatment of HepG2 cells for 24, 48, and 72h inhibited cell proliferation in a concentration- and time-dependent manner and induced apoptosis. Echinacoside (50, 100μg/mL) treatment of HepG2 cells for 48h significantly reduced p-AKT protein levels and upregulated the protein expression of p21 and Bax[5]. Echinacoside (0.1, 1, 10nM) treatment of MC3T3-E1 cells for 21 days dose-dependently and significantly promoted mineralized nodule formation[6].
In vivo, intragastric administration of Echinacoside (30, 90, 270mg/kg/day) to ovariectomized rats for 12 weeks significantly increased osteoprotegerin levels and decreased receptor activator of nuclear factor-κB ligand (RANKL) levels[7]. A single oral dose of Echinacoside (250, 500mg/kg) administered to starch-loaded mice significantly inhibited the postprandial increase in blood glucose levels, with blood glucose levels in the 500mg/kg dose group being significantly lower than those in the control group at 0.5, 1, and 2h[8].
References:
[1] LIU J, YANG L, DONG Y, et al. Echinacoside, an inestimable natural product in treatment of neurological and other disorders[J]. Molecules, 2018, 23(5): 1213.
[2] LI J, YU H, YANG C, et al. Therapeutic potential and molecular mechanisms of echinacoside in neurodegenerative diseases[J]. Frontiers in Pharmacology, 2022, 13: 841110.
[3] SHEOKAND A, KOLI D, WADHWA K, et al. Mechanistic insights into the anticancer potential of echinacoside: therapeutic applications and future directions[J]. Archiv der Pharmazie, 2025, 358(11): e70153.
[4] LI L, RAN Y, WEN J, et al. Traditional Chinese medicine-based treatment in cardiovascular disease: potential mechanisms of action[J]. Current Pharmaceutical Biotechnology, 2024, 25(17): 2186-2199.
[5] YE Y, SONG Y, ZHUANG J, et al. Anticancer effects of echinacoside in hepatocellular carcinoma mouse model and HepG2 cells[J]. Journal of Cellular Physiology, 2019, 234(2): 1880-1888.
[6] LI F, YANG Y, ZHU P, et al. Echinacoside promotes bone regeneration by increasing OPG/RANKL ratio in MC3T3-E1 cells[J]. Fitoterapia, 2012, 83(8): 1443-1450.
[7] WU L, GEORGIEV M I, CAO H, et al. Therapeutic potential of phenylethanoid glycosides: a systematic review[J]. Medicinal Research Reviews, 2020, 40(6): 2605-2649.
[8] MORIKAWA T, NINOMIYA K, IMAMURA M, et al. Acylated phenylethanoid glycosides, echinacoside and acteoside from Cistanche tubulosa, improve glucose tolerance in mice[J]. Journal of Natural Medicines, 2014, 68(3): 561-566.
| Cell experiment [1]: | |
Cell lines | HepG2 cells |
Preparation Method | HepG2 cells were exposed to various doses of Echinacoside (50, 100μg/mL). After 48h, the western blot analysis was performed to assess the expression of p‐AKT, p21, and Bax. |
Reaction Conditions | 50, 100μg/mL; 48h |
Applications | Treatment of Echinacoside significantly reduced p-AKT protein levels and upregulated p21 and Bax protein expression. |
| Animal experiment [2]: | |
Animal models | Starch-loaded ddY mice |
Preparation Method | A mixture of Echinacoside (250, 500mg/kg) and α-starch (1g/kg) suspended in 5% (w/v) acacia solution was administered orally to fasted mice. Blood samples were collected from the infraorbital venous plexus under ether anesthesia at 0.5, 1, and 2h after oral administration, and plasma glucose levels were determined enzymatically by the Glucose CII test Wako. |
Dosage form | 250, 500mg/kg; p.o. |
Applications | Treatment of Echinacoside significantly inhibited the rise in postprandial blood glucose in starch-loaded mice, with blood glucose levels at 0.5h, 1h, and 2h significantly lower than those in the control group at a dose of 500mg/kg. |
References: | |
| Cas No. | 82854-37-3 | SDF | |
| Synonyms | Kusaginin, NSC 603831, trans-Acteoside, trans-Verbascoside | ||
| Chemical Name | [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate | ||
| Canonical SMILES | CC1C(C(C(C(O1)OC2C(C(OC(C2OC(=O)C=CC3=CC(=C(C=C3)O)O)COC4C(C(C(C(O4)CO)O)O)O)OCCC5=CC(=C(C=C5)O)O)O)O)O)O | ||
| Formula | C35H46O20 | M.Wt | 786.72 |
| Solubility | ≥ 78.7mg/mL in DMSO | Storage | Store at 2-8°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2711 mL | 6.3555 mL | 12.711 mL |
| 5 mM | 254.2 μL | 1.2711 mL | 2.5422 mL |
| 10 mM | 127.1 μL | 635.6 μL | 1.2711 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)